CPNP 2020 industry supported symposia are scientific programs developed for educational purposes. All symposia at CPNP 2020 are designed for the psychiatric pharmacist and are included in participant registration fees. All symposia are in compliance with Accreditation Council for Pharmacy Education (ACPE) criteria for planning and implementation and provide 1.5 contact hours of ACPE credit.
Tremendous interest has been generated in the medicinal potential from derivatives of the Cannabis species. The popularity of cannabidiol (CBD) oils for a huge variety of purposes has exploded, seemingly overnight. Intermixed with the excitement and hope is confusion about the many substances that can be derived from both the hemp and Cannabis sativa plants, how they differ from street drugs or home-grown, and how patients with serious illnesses can benefit from these agents in a safe and consistent manner. The legal/regulatory landscape for these substances are even more confusing.
This compelling symposium will provide a greater understanding of CBD and medical marijuana including a better understanding of the distinctions between Cannabis-derived substances such as CBD, including legal issues, purity, safety and efficacy of the FDA approved CBD agent, OTC CBD products and “street” products.
Jacquelyn L. Bainbridge, PharmD, FCCP
Professor, Clinical Pharmacy & Department of Neurology
University of Colorado Anschutz Medical Campus Skaggs School of Pharmacy
Laura Borgelt, PharmD, MBA, FCCP, BCPS
Professor and Associate Dean of Administration and Operations
Clinical Pharmacy and Family Medicine
University of Colorado Anschutz Medical Campus
Skaggs School of Pharmacy
Despite advances in treatment, schizophrenia continues to be one of the most challenging diseases for clinical pharmacists to manage. Antipsychotic medications are a mainstay of therapy, but they are also associated with high rates of nonadherence among patients, approaching 50% within the first year of treatment. Clinical psychiatric pharmacists must review patient-centered management strategies and assess appropriateness of therapy. Leveraging knowledge of efficacy, safety, and administration of pharmaceutical agents in clinical practice settings will allow pharmacists involved in the care of patients with schizophrenia to guide treatment decisions and improve overall patient outcomes. This activity will review the current treatment landscape of schizophrenia as well as evidence for novel therapies that have the potential to improve symptom management, optimize adherence, and reduce adverse effects.
Lindsey N. Miller, PharmD, BCPP
Department of Pharmacy Practice
Lipscomb University College of Pharmacy
Clinical Psychiatric Pharmacist
Vanderbilt Psychiatric Hospital
Megan Maroney, PharmD, BCPP
Clinical Associate Professor
Ernest Mario School of Pharmacy
Rutgers, the State University of New Jersey
Clinical Psychiatric Pharmacist
Monmouth Medical Center
Long Branch, New Jersey
All patients prescribed an antipsychotic medication are at risk of developing tardive dyskinesia. Treatment for this disorder was once bleak, but with the developments and approval of VMAT2 inhibitors over the last few years, that has drastically changed. In this session, expert faculty will review the latest data on effective VMAT2 inhibitor treatment and demonstrate how to incorporate these medications into everyday clinical practice to improve the lives of patients with TD.
Christoph U. Correll, MD
Professor of Psychiatry
Zucker School of Medicine at Hofstra/Northwell
Floral Park, New York
Stephen R. Saklad, PharmD, BCPP
Clinical Professor and Director of Psychiatric Pharmacy
The University of Texas at Austin
College of Pharmacy, Pharmacotherapy Division
Shavano Park, Texas
In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit can be claimed online.
North American Center for Continuing Medical Education (NACCME), an HMP Company
Neurocrine Biosciences and Teva Pharmaceuticals